Irrimax Corporation Continues Strategic Expansion in Targeted International Markets
Smile Digital Health Expands Work on AWS
Smile CDR Inc. (doing business as Smile Digital Health), a leading health data and integration company, today announced it has passed an Amazon Web Services (AWS) Foundational Technical Review (FTR) and has achieved Amazon HealthLake (AHL) Connector partner status in the AWS Partner Network (APN). Healthcare organizations can expect Smile Digital Health running on AWS to provide a best-in-class data fabric platform along with the confidence that it is meeting various regulatory and compliance requirements in the U.S. and the EU when storing and sharing their sensitive health data via the platform. Smile Digital Health first announced its work with AWS in March, and this expansion represents the continual growth of that relationship.
"Our ongoing work with AWS demonstrates the deep collaboration between our companies, delivering the many benefits of the Smile Digital Health data fabric platform running in a world-class hyperscale environment. Having partner status provides our customers with substantial benefits including additional security, dependability and operational excellence," said Duncan Weatherston, Chief Executive Officer, Smile Digital Health. "Healthcare organizations — and in turn their patients — are well served by access to our scalable, high-performing, resilient and efficient data fabric platform on the leading cloud infrastructure."
The expansion and scope of work includes two key elements:
-
Becoming an Amazon HealthLake (AHL) Connector Partner, demonstrating the company's ability to help transform existing healthcare data in real time into the required format, including standard Fast Healthcare Interoperability Resources (FHIR®) format, so the data can be used across AHL applications and services.
- Passing the AWS Foundational Technical Review (FTR), which helps identify and mitigate technical risks in solutions built by independent software vendors (ISVs). Smile Digital Health's solutions were evaluated by a subset of AWS Well-Architected best practices. As part of the review, Smile Digital Health's reference architecture was approved to be deployed on Amazon Elastic Kubernetes Services (Amazon EKS), a managed container service to run and scale Kubernetes applications in the cloud or on-premises, and Amazon Aurora and Amazon Relational Database Service (Amazon RDS) for PostgreSQL to ensure a performant, cost-effective, secure and scalable solution.
"Our customers can expect Smile Digital Health to continuously meet and often exceed regulatory and compliance requirements when storing and sharing their sensitive health data via our data fabric platform. In that sense, we continue to guarantee the highest security and compliance standards," said James Agnew, Chief Technology Officer, Smile Digital Health.
Smile Digital Health's work on AWS continues to simplify the interoperability process between various data platforms, allowing for better health journey outcomes between patients, providers and health systems, and reducing information technology barriers.
About Smile Digital Health
Smile Digital Health is a health information technology company focused on delivering better global health through open standards. Our enterprise-grade, health data fabric and exchange platform fuels healthcare's digital transformation and accelerates value creation across all patient journeys at scale. Powered by our HL7® FHIR® standard-based clinical data repository (#SmileInside), our platform enables collaboration and allows organizations to ingest, transform, store, enrich, analyze, aggregate, and meaningfully share health information to power digital transformation. We prepare healthcare providers, payers, researchers, and life sciences organizations for a connected future beyond legacy systems, adding new value through intelligent use of information and ultimately delivering better patient outcomes. We help healthcare organizations confidently #ChooseOpenStandards with the goal of #BetterGlobalHealth. For more information, visit SmileDigitalHealth.com.
Contact Information:
Lucy Railton
Director of Marketing
[email protected]
(800) 683-1318
Press Release Service by Newswire.com
Original Source: Smile Digital Health Expands Work on AWS
TEC Mailing Solutions’ New Service Addresses Direct-to-Consumer Fulfillment Challenges
MADISON, Wis. - October 12, 2022 - (Newswire.com)
TEC Mailing Solutions, LLC, launches new service to improve the deliverability of life saving, direct-to-consumer pharmaceuticals to track the changes of new mover data.
Just like the waves of an ocean, the population continues to ebb and flow nationally at the rate of thousands of people per day. The migration has been steadily building in Fort Myers for the last decade and now the flow is retracting, as thousands of misplaced households are on the move in a small region.
No matter how or which way the population flows, it is creating new challenges for cadence-based shippers, those fulfilling subscriptions and more importantly life-saving prescriptions. Residents of Fort Myers who were receiving their medications through the mail will be unable to obtain vital packages.
The best data source to track new residences and address changes is the USPS National Change of Address database, which maintains move update information for the prior 48 months. Providers like TEC Mailing Solutions have unique features for the pharmaceutical industry that apply to anyone who has moved and filed a change of address with the postal service.
"We've been tracking live return data from our Pharmaceutical clients and effectively implementing safeguards to ensure our clients enjoy the best deliverability," explains President Brian Euclide, President of TEC Mailing Solutions. "Returns due to change of address is a billion-dollar problem. This is a challenge we're honored to solve."
There will be lessons learned from IAN. Data will reveal the scale of devastation. Thankfully, there is new thinking and technology from private industry taking these challenges head-on. TEC Mailing's Verify & Confirm™ product stops orders and packages from going to vacant or abandoned homes, buildings and people who have recently moved. Verify & Confirm™ also finds the current address of those who have filed a change of address. TEC Mailing ensures that each address is not only correct and complete but also current, in a first-of-its-kind implementation, specifically for direct-to-consumer pharmaceutical fulfillment.
About: TEC Mailing Solutions LLC is a Software as a Service (SaaS) provider of name, address hygiene, bulk mail and parcel sortation services for web-to-print, CRM, OEM, ERP, and variable digital printing solutions. TEC Mailing's services are embedded functions in applications to improve workflow or standalone web portals: MailListCleaner®, MailPreparer™, MailPieceTracker™, ParcelPrep™, and Verify & Confirm are available direct or through a network of resell/referral partners and VARs. Privately held, the corporate office is in Sun Prairie, Wisconsin. Find more information at http://www.tecmailing.com or call 866-379-9437.
Contact Information:
Scott Eganhouse
VP
[email protected]
16082175515
Press Release Service by Newswire.com
Original Source: TEC Mailing Solutions' New Service Addresses Direct-to-Consumer Fulfillment Challenges
Apgar & Associates Achieves HITRUST® Readiness Licensee Designation
PORTLAND, Ore. - October 12, 2022 - (Newswire.com)
Apgar & Associates, LLC today announced that it is designated as a HITRUST Readiness Licensee. With this achievement, Apgar & Associates is approved by HITRUST to perform consulting and readiness work for organizations looking to adopt the HITRUST CSF or prepare for their first assessment. For over a decade, the consultancy has provided information security and privacy services that encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.
HITRUST Readiness Licensees help uphold information security and privacy standards for various industries of varying size and complexity by assisting clients with the adoption of the HITRUST CSF framework, implementation, and remediation efforts following adoption, and facilitated self-assessments.
"We're very pleased to receive the HITRUST Readiness designation. It feels like a natural progression in our firm's commitment to furthering excellence in the healthcare sector's information security and privacy programs," stated Julia Huddleston, CIPP/US, CIPM, CCSFP, and Principal Consultant at Apgar & Associates, LLC. "We look forward to helping guide healthcare providers and their business associates through the what and how of readying for the HITRUST assessment."
"Readiness Licensees meet the criteria to become trusted and independent resources for clients needing to improve their security posture," said Matthew Datel, Director, Education & Strategic Initiatives at HITRUST. "Readiness Licensees are helpful in providing qualified third-party reviews for clients preparing for or seeking HITRUST CSF Certification."
About Apgar & Associates
The consultancy's information security and privacy services encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.
The team also helps organizations decide which of the various industry certifications aligns best with the business' privacy and information security strategy. For more information about Apgar & Associates' consulting services, such as HITRUST Readiness, please contact the company at 503-384-2538 or visit its website at https://apgarandassoc.com/.
Contact Information:
Nora Haile
Marketing Consultant
[email protected]
520-425-6498
Press Release Service by Newswire.com
Original Source: Apgar & Associates Achieves HITRUST® Readiness Licensee Designation
Group Dentistry Now and Seattle Study Club Enter Into a Strategic Agreement to Bring...
Troomy Nootropics Launches Line of All-Natural, Functional Mushroom Gummies
ChangeNOW Shares Its Internal Review of the BNB Smart Chain Hack
The Animal Eye Institute Announces a New Location in Charleston, South Carolina
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs)...
Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit's data-driven methodology for projecting prevalence and diagnosis rates for difficult-to-quantify DEEs at the 51st Annual Child Neurology Society Meeting on Oct. 13, 2022. Ambit's analytics team has developed this methodology in collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX) and the UCSF Weill Institute for Neurosciences and Benioff Children's Hospitals.
For many rare DEEs, reliable prevalence estimates are not available. With a robust and growing pipeline of precision medicine therapies in rare epilepsy and neurodevelopmental disorders, estimating the prevalence of these conditions with a data-driven methodology can be highly valuable to drug developers, medical device companies and other healthcare decision-makers.
"Ambit's expertise in a data-driven approach to prevalence projections for rare neurological conditions has allowed Praxis to characterize DEE populations with a high degree of confidence," said Marcio Souza, president and chief executive officer of Praxis. "As we seek to bring first-in-class, potentially disease-modifying therapies to DEE patients in need, our collaboration with Ambit has been invaluable in increasing our understanding of these patient groups."
Despite the availability of sponsored genetic testing and increased awareness of the benefit of genetic testing, over 50% of patients with rare DEEs remain undiagnosed. Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs. "Even today, the path to accurate diagnosis and appropriate care for rare genetic epilepsies can be long and full of challenges," said Adam Numis, M.D., of the UCSF Benioff Children's Hospital. "Ambit's methodology underscores the need for more treatment options to improve outcomes and quality of life for the rare DEE population."
Ambit chief executive officer, Robert Sederman, will present this methodology on Oct. 13 as part of the Platform II Presentation Session (PL2-1) at the 2022 Annual Child Neurology Society Meeting. Presentations will run from 7-9 a.m. ET in the Junior Ballroom CD at the Duke Energy Center. Ambit will be presenting from 7-7:15 a.m. The associated abstract will be published in a supplement to the October issue of Annals of Neurology.
"We are excited to partner with Praxis and UCSF to showcase Ambit's DEE projection methodology at this year's meeting and, ultimately, see the impact of this collaboration on greater access to accurate diagnosis and treatment for patients with rare DEEs in the future," said Sederman.
About Ambit Inc.
Ambit Inc.® is a data and technology-enabled biopharma and healthcare services company with a focus on rare and specialty disease. Ambit's patient identification services drive patient activation and earlier diagnosis for patients that may be suffering from rare diseases. Ambit's analytics and professional services support rare and specialty biopharma across the clinical development and commercialization of potentially life-changing therapies. To learn more about Ambit's DEE Projection approach and other capabilities, please reach out to [email protected].
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.
Contact Information:
Alexis Burbank
Marketing, Ambit Inc.
[email protected]
Press Release Service by Newswire.com
Original Source: Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
